Previous 10 | Next 10 |
2024-01-03 07:00:00 ET Summary The biotech industry experienced a challenging year in 2023 due to a rising 10-year Treasury yield. In 2024, the 10-year yield should favorably support biotech stocks. Promising advancements in weight loss drugs, neuroscience, oncology, and gene ...
2024-01-02 00:58:59 ET Summary Casgevy's FDA approval is a key advance in gene editing for SCD, yet it faces high costs and a limited market due to specialized treatment needs. Casgevy's complex treatment, including stem cell processes, necessitates costly, specialized centers, li...
2024-01-01 09:05:00 ET It may seem like $100 isn't a lot of money to invest in the stock market. But over time, you can add to that total and grow your stake in a business. Investing even a small amount is a good way to at least get your feet wet and slowly gain some exposure to a stock wit...
2023-12-31 08:45:00 ET With the launch of its first gene therapy that's near-curative for sickle cell disease (SCD), everyone's talking about CRISPR Therapeutics (NASDAQ: CRSP) and its collaboration partner Vertex Pharmaceuticals . But CRISPR isn't the only biotech pursuing ...
2023-12-30 06:50:00 ET Finding stocks that are huge winners is easy, in retrospect. Doing so before they take off is an entirely different story. However, it's not an impossible task. Three Motley Fool contributors think they've identified stocks that could be monster winners in 2024. H...
2023-12-29 19:03:08 ET More on CRISPR Therapeutics Vertex And CRISPR Therapeutics: Historic Exa-cel Approval, Why Market Is Nonplussed CRISPR Gene Editing: Intellia Vs. Crispr Therapeutics Crispr Therapeutics: The Party Is Over (Rating Downgrade) Cell and gen...
2023-12-29 17:15:31 ET More on bluebird bio, CRISPR Therapeutics, etc. bluebird bio's Lyfgenia: Navigating Commercialization Challenges In SCD Vertex's Pain Game: VX-548 Takes Aim At Neuropathic Battles Vertex And CRISPR Therapeutics: Historic Exa-cel Approval, Why M...
2023-12-28 13:10:55 ET Summary Editas Medicine is transitioning from platform development to establishing itself as a key player in the commercial therapeutics market. The company's strategic priorities include fast-tracking the clinical development of EDIT-301, shifting focus to ...
2023-12-25 23:44:10 ET Summary Editas Therapeutics is developing a gene-editing therapy called reni-cel for Sickle Cell Disease and beta-thalassemia. The competitive landscape for gene-editing therapies for SCD is strengthening with three leading contenders: Casgevy by Vertex Phar...
2023-12-25 10:03:02 ET Summary I discuss my investment and trading strategies before and after March 2022. I highlight the importance of trade income, capital gains, dividend collection, and tax harvesting in my investment approach. I want to see the Bull Plateau (or Bear-Mark...
News, Short Squeeze, Breakout and More Instantly...
CRISPR Therapeutics AG Company Name:
CRSP Stock Symbol:
NASDAQ Market:
CRISPR Therapeutics AG Website:
2024-07-17 10:10:00 ET July 17, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the first of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:CTXR ), a late-stage biopharmaceutical compan...